Compare Torrent Pharma with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs UNICHEM LAB - Comparison Results

TORRENT PHARMA     Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA UNICHEM LAB TORRENT PHARMA/
UNICHEM LAB
 
P/E (TTM) x 36.3 -44.1 - View Chart
P/BV x 9.2 1.1 849.2% View Chart
Dividend Yield % 0.7 1.3 51.8%  

Financials

 TORRENT PHARMA   UNICHEM LAB
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-19
UNICHEM LAB
Mar-19
TORRENT PHARMA/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs1,964292 672.6%   
Low Rs1,245182 684.1%   
Sales per share (Unadj.) Rs453.4167.7 270.4%  
Earnings per share (Unadj.) Rs25.8-3.6 -710.2%  
Cash flow per share (Unadj.) Rs62.35.9 1,048.3%  
Dividends per share (Unadj.) Rs17.004.00 425.0%  
Dividend yield (eoy) %1.11.7 62.8%  
Book value per share (Unadj.) Rs279.2372.3 75.0%  
Shares outstanding (eoy) m169.2270.38 240.4%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.51.4 250.3%   
Avg P/E ratio x62.2-65.3 -95.3%  
P/CF ratio (eoy) x25.839.9 64.6%  
Price / Book Value ratio x5.70.6 902.7%  
Dividend payout %65.9-110.2 -59.8%   
Avg Mkt Cap Rs m271,51316,680 1,627.8%   
No. of employees `00013.62.6 522.6%   
Total wages/salary Rs m14,0382,393 586.6%   
Avg. sales/employee Rs Th5,642.64,535.2 124.4%   
Avg. wages/employee Rs Th1,032.4919.8 112.2%   
Avg. net profit/employee Rs Th320.9-98.2 -326.7%   
INCOME DATA
Net Sales Rs m76,72811,801 650.2%  
Other income Rs m571984 58.0%   
Total revenues Rs m77,29912,785 604.6%   
Gross profit Rs m19,831-835 -2,375.2%  
Depreciation Rs m6,177674 916.9%   
Interest Rs m5,03875 6,698.8%   
Profit before tax Rs m9,187-600 -1,531.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m-3,5700-   
Tax Rs m1,254-343 -365.0%   
Profit after tax Rs m4,363-256 -1,707.5%  
Gross profit margin %25.8-7.1 -365.3%  
Effective tax rate %13.657.3 23.8%   
Net profit margin %5.7-2.2 -262.6%  
BALANCE SHEET DATA
Current assets Rs m50,37520,384 247.1%   
Current liabilities Rs m51,6535,029 1,027.1%   
Net working cap to sales %-1.7130.1 -1.3%  
Current ratio x1.04.1 24.1%  
Inventory Days Days92105 87.9%  
Debtors Days Days68135 50.6%  
Net fixed assets Rs m83,6489,023 927.0%   
Share capital Rs m846141 601.0%   
"Free" reserves Rs m46,39726,058 178.1%   
Net worth Rs m47,24426,199 180.3%   
Long term debt Rs m39,1290-   
Total assets Rs m141,20931,496 448.3%  
Interest coverage x2.8-7.0 -40.5%   
Debt to equity ratio x0.80-  
Sales to assets ratio x0.50.4 145.0%   
Return on assets %6.7-0.6 -1,162.7%  
Return on equity %9.2-1.0 -946.9%  
Return on capital %12.3-2.0 -617.0%  
Exports to sales %069.4 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA8,188 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m22,1038,188 269.9%   
Fx outflow Rs m5,522596 926.4%   
Net fx Rs m16,5817,592 218.4%   
CASH FLOW
From Operations Rs m17,981-3,278 -548.6%  
From Investments Rs m-2,413-2,860 84.4%  
From Financial Activity Rs m-13,145-24 54,316.1%  
Net Cashflow Rs m2,380-4,690 -50.7%  

Share Holding

Indian Promoters % 71.5 50.1 142.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 15.1 46.5%  
FIIs % 12.6 3.0 420.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 31.7 27.8%  
Shareholders   26,511 20,176 131.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   ORCHID PHARMA  CIPLA  ASTRAZENECA PHARMA  AUROBINDO PHARMA  STERLING BIOTECH  

Compare TORRENT PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

India Top US Crude Oil Buyer in Q1CY21, Adani Ports Removed from S&P Index, and Buzzing Stocks Today(Pre-Open)

Indian share markets ended on a strong note on Tuesday. Benchmark indices extended gains after the Indian government fast-tracked emergency approvals for foreign produced Covid-19 vaccines.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 27.0% (Quarterly Result Update)

Oct 27, 2020 | Updated on Oct 27, 2020

For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 48.6% (Quarterly Result Update)

Jul 31, 2020 | Updated on Jul 31, 2020

For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 2.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 2.0% YoY). Sales on the other hand came in at Rs 20 bn (down 4.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

UNICHEM LAB Announces Quarterly Results (1QFY20); Net Profit Up 102.2% (Quarterly Result Update)

Jul 30, 2019 | Updated on Jul 30, 2019

For the quarter ended June 2019, UNICHEM LAB has posted a net profit of Rs 5 m (up 102.2% YoY). Sales on the other hand came in at Rs 2 bn (up 15.4% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

An India Revival Stock I'm Bullish On...(Profit Hunter)

Apr 9, 2021

This could take India to the position of 3rd largest economy.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

Why the Market Fell Yesterday(Fast Profits Daily)

Apr 6, 2021

In this video, I'll tell you the two reasons why the market fell on Monday and how you can prepare yourself for such events in the future.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Apr 13, 2021 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS